Immunome Inc. (IMNM): M&A transaction — Immunome completes acquisition of Ayala's AL102 Phase 3 desmoid tumor asset for $20M cash + stock

Immunome Inc.

Acquisition of AL102 (Phase 3 gamma secretase inhibitor) and AL101; upfront $20M cash and 2,175,489 shares to Ayala.
Potential milestone payments up to $37.5M upon development and commercial milestones.
BMS license assumed: up to $142M clinical/regulatory milestones + $50M commercial milestones per product; royalties high single to low teen % on net sales.
CEO states AL102 may establish new standard of care for desmoid tumors; preclinical programs advancing to Phase 1.

item 2.01 item 1.01 item 3.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

Immunome Inc. completed an acquisition involving Ayala Pharmaceuticals, Inc. for $20.0 million in cash (closed 2024-03-25).

Action: acquisition
Counterparty: Ayala Pharmaceuticals, Inc.
Consideration: $20.0 million in cash
Closing: 2024-03-25

Exact text from the filing

by reference. Item 2.01 Completion of Acquisition or Disposition of Assets Pursuant to the terms of the Asset Purchase Agreement, Immunome (i) paid an upfront purchase price of $20.0 million in cash to Ayala, less certain adjustments, (ii) issued Ayala 2 ,175,489 shares of Immunome’s common stock (the “Shares”), (iii) assumed specified liabilities from Ayala, and

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.7

Immunome Inc. entered into BMS License with Bristol-Myers Squibb Company valued at up to approximately $142 million.

Action: entry
Agreement: license
Counterparty: Bristol-Myers Squibb Company
Value: up to approximately $142 million

Exact text from the filing

In November 2017, Ayala entered into a License Agreement with Bristol-Myers Squibb Company (“BMS”), as amended by that certain First Amendment to License Agreement dated as of May 4, 2020 (the “BMS License”).

View on SEC.gov

91 m&a transactions filed in the last 30 days. Browse all m&a transactions →

Immunome Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-038744

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.